Overview

Growth of $10,000

10-year period ended 06/30/2016

  • Class A at NAV

Historical Returns (%)as of Jun 30, 2016

Annualized
1 Mo. 3 Mos. YTD 1 Yr. 3 Yrs. 5 Yrs. 10 Yrs.
07/31/2016
Fund at NAV 5.40 5.68 -2.98 -9.35 15.84 16.20 11.41
Fund w/Max Sales Charge -0.68 -0.42 -8.58 -14.58 13.58 14.83 10.76
MSCI World Health Care Index1 4.55 6.86 2.86 -4.33 12.47 15.34 8.92
06/30/2016
Fund at NAV -2.37 3.73 -7.95 -10.92 16.47 14.44 11.08
Fund w/Max Sales Charge -7.95 -2.20 -13.26 -16.06 14.21 13.08 10.42
MSCI World Health Care Index1 0.80 5.59 -1.61 -4.60 12.87 13.94 8.84
Past performance is no guarantee of future results. Investment return and principal value will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. Performance is for the stated time period only; due to market volatility, the Fund's current performance may be lower or higher than quoted. Returns are historical and are calculated by determining the percentage change in net asset value (NAV) with all distributions reinvested. Returns for other classes of shares offered by the Fund are different. Performance less than or equal to one year is cumulative. Max Sales Charge: 5.75%.

Fund Factsas of Jul 31, 2016

Class A Inception 07/26/1985
Investment Objective Long-term capital growth
Total Net Assets $1.5B
Minimum Investment $1000
Expense Ratio2 1.34%
CUSIP 277902813

Top 10 Holdings (%)3,4as of Jun 30, 2016

Boston Scientific Corp
AbbVie Inc
Intuitive Surgical Inc
Ono Pharmaceutical Co Ltd
Allergan plc
Amgen Inc
HCA Holdings Inc
Bristol-Myers Squibb Co
Eli Lilly & Co
Alexion Pharmaceuticals Inc
Total 43.82

Portfolio Management

Jason Kritzer, CFA Managed Fund since 2016
Samantha Pandolfi, CFA Managed Fund since 2016

Portfolio profile subject to change due to active management. Percentages may not total 100% due to rounding. Fund invests in an affiliated investment company (Portfolio) with the same objective(s) and policies as the Fund. References to investments are to the Portfolio's holdings.

About Risk 

Fund performance is sensitive to stock market volatility. Because the Fund investments may be concentrated in a particular industry, the Fund share value may fluctuate more than that of a less concentrated fund. Investments in foreign instruments or currencies can involve greater risk and volatility than U.S. investments because of adverse market, economic, political, regulatory, geopolitical or other conditions. Smaller companies are generally subject to greater price fluctuations, limited liquidity, higher transaction costs and higher investment risk than larger, established companies. No Fund is a complete investment program and you may lose money investing in a Fund. The Fund may engage in other investment practices that may involve additional risks and you should review the Fund prospectus for a complete description.


Performance

Historical Returns (%)as of Jun 30, 2016

Annualized
1 Mo. 3 Mos. YTD 1 Yr. 3 Yrs. 5 Yrs. 10 Yrs.
07/31/2016
Fund at NAV 5.40 5.68 -2.98 -9.35 15.84 16.20 11.41
Fund w/Max Sales Charge -0.68 -0.42 -8.58 -14.58 13.58 14.83 10.76
MSCI World Health Care Index1 4.55 6.86 2.86 -4.33 12.47 15.34 8.92
Morningstar™ Health Category5 6.74 7.75 -3.46 -12.49 14.19 17.81 11.76
06/30/2016
Fund at NAV -2.37 3.73 -7.95 -10.92 16.47 14.44 11.08
Fund w/Max Sales Charge -7.95 -2.20 -13.26 -16.06 14.21 13.08 10.42
MSCI World Health Care Index1 0.80 5.59 -1.61 -4.60 12.87 13.94 8.84
Morningstar™ Health Category5 -1.96 4.43 -9.43 -15.14 15.00 15.57 11.23
Past performance is no guarantee of future results. Investment return and principal value will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. Performance is for the stated time period only; due to market volatility, the Fund's current performance may be lower or higher than quoted. Returns are historical and are calculated by determining the percentage change in net asset value (NAV) with all distributions reinvested. Returns for other classes of shares offered by the Fund are different. Performance less than or equal to one year is cumulative. Max Sales Charge: 5.75%.

Calendar Year Returns (%)

2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Fund at NAV -0.01 6.49 -7.24 9.89 11.13 4.75 15.49 44.56 27.39 8.39
MSCI World Health Care Index1 10.47 3.94 -21.50 18.89 2.41 9.46 17.54 36.27 18.10 6.60

Fund Facts

Expense Ratio2 1.34%
Class A Inception 07/26/1985
Distribution Frequency Annually

Risk Measures (3 Year)6as of Jul 31, 2016

Alpha (%) 1.11
Beta 1.19
R-Squared (%) 81.84
Standard Deviation (%) 15.45
Sharpe Ratio 1.02

Morningstar™ Ratingsas of Jul 31, 2016

Time Period Rating Rating (Load Waived) Funds in
Health
Category
Overall *** *** 123
3 Years *** *** 123
5 Years ** *** 114
10 Years *** *** 93
Based on Risk-Adjusted Returns.

The Overall Morningstar Rating for a fund is derived from a weighted average of the performance figures associated with its 3-, 5- and 10-year (if applicable) Morningstar Rating metrics.

© 2016 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers is responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. For each fund with at least a three-year history, Morningstar calculates a Morningstar Rating™ based on how a fund ranks on a Morningstar Risk-Adjusted Return measure against other funds in the same category. This measure takes into account variations in a fund's monthly performance after adjusting for sales loads (except for load-waived A shares) redemption fees, and the risk-free rate, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of funds in each category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars and the bottom 10% receive 1 star. Load-waived A share star ratings do not include any front-end sales load and are intended for those investors who have access to such purchase terms (e.g., plan participants of a defined contribution plan). Not all A share mutual funds for which Morningstar calculates a load-waived A share star rating may actually waive their front-end sales load. Therefore, Morningstar strongly encourages investors to contact their investment professional to determine whether they are eligible to purchase the A share without paying the front load. The Morningstar Rating may differ among share classes of a mutual fund as a result of different sales loads and/or expense structure.

NAV History

Date NAV NAV Change
Aug 26, 2016 $11.23 $0.01
Aug 25, 2016 $11.22 -$0.11
Aug 24, 2016 $11.33 -$0.23
Aug 23, 2016 $11.56 $0.03
Aug 22, 2016 $11.53 $0.13
Aug 19, 2016 $11.40 -$0.01
Aug 18, 2016 $11.41 $0.00
Aug 17, 2016 $11.41 -$0.02
Aug 16, 2016 $11.43 -$0.09
Aug 15, 2016 $11.52 $0.05
View All

Distribution History7

Ex-Date Distribution Reinvest NAV
Dec 17, 2013 $0.06940 $10.78
No records in this table indicates that there has not been a distribution greater than .0001 within the past 3 years.
Fund prospectus

Capital Gain History7

Ex-Date Short-Term Long-Term Reinvest NAV
Dec 15, 2015 $0.15340 $1.01810 $11.82
Dec 16, 2014 $0.56450 $1.45310 $11.95
Dec 17, 2013 $0.19790 $1.16690 $10.78
No records in this table indicates that there has not been a capital gain greater than .0001 within the past 3 years.
Fund prospectus

Portfolio profile subject to change due to active management. Percentages may not total 100% due to rounding. Fund invests in an affiliated investment company (Portfolio) with the same objective(s) and policies as the Fund. References to investments are to the Portfolio's holdings.

About Risk 

Fund performance is sensitive to stock market volatility. Because the Fund investments may be concentrated in a particular industry, the Fund share value may fluctuate more than that of a less concentrated fund. Investments in foreign instruments or currencies can involve greater risk and volatility than U.S. investments because of adverse market, economic, political, regulatory, geopolitical or other conditions. Smaller companies are generally subject to greater price fluctuations, limited liquidity, higher transaction costs and higher investment risk than larger, established companies. No Fund is a complete investment program and you may lose money investing in a Fund. The Fund may engage in other investment practices that may involve additional risks and you should review the Fund prospectus for a complete description.


Portfolio

Asset Mix (%)4,8as of Jun 30, 2016

U.S. Common Stocks 73.30
Foreign Common Stocks 17.65
Cash 9.06
Total 100.00

Portfolio Statisticsas of Jun 30, 2016

Number of Holdings 37

Sector Breakdown (%)4as of Jun 30, 2016

Sector Fund MSCI World Health Care Index1
Biotechnology 33.42 16.79
Health Care Distributors 0.00 2.62
Health Care Equipment 12.50 12.33
Health Care Facilities 3.77 1.31
Health Care Services 1.67 3.70
Health Care Supplies 2.43 1.73
Health Care Technology 0.00 0.68
Life Sciences Tools & Services 3.57 3.15
Managed Health Care 5.54 6.64
Pharmaceuticals 28.05 51.06
Cash 9.06 0.00

Assets by Country (%)4as of Jun 30, 2016

United States 74.34
Switzerland 6.32
Japan 6.14
Denmark 2.26
Israel 1.88
Cash & Other Assets 9.06
Total 100.00

Geographic Mix (%)4as of Jun 30, 2016

North America 74.34
Europe 8.59
Asia/Pacific 6.14
Middle East 1.88
Cash & Other Assets 9.06
Total 100.00

Fund Holdings (%)4,9as of Jun 30, 2016

Holding % of Net Assets
EV Cash Reserves Fund 9.05%
Boston Scientific Corp 6.27%
AbbVie Inc 5.24%
Intuitive Surgical Inc 5.03%
Ono Pharmaceutical Co Ltd 4.79%
Allergan plc 4.36%
Amgen Inc 4.24%
HCA Holdings Inc 3.78%
Bristol-Myers Squibb Co 3.58%
Eli Lilly & Co 3.33%
View All

Portfolio profile subject to change due to active management. Percentages may not total 100% due to rounding. Fund invests in an affiliated investment company (Portfolio) with the same objective(s) and policies as the Fund. References to investments are to the Portfolio's holdings.

About Risk 

Fund performance is sensitive to stock market volatility. Because the Fund investments may be concentrated in a particular industry, the Fund share value may fluctuate more than that of a less concentrated fund. Investments in foreign instruments or currencies can involve greater risk and volatility than U.S. investments because of adverse market, economic, political, regulatory, geopolitical or other conditions. Smaller companies are generally subject to greater price fluctuations, limited liquidity, higher transaction costs and higher investment risk than larger, established companies. No Fund is a complete investment program and you may lose money investing in a Fund. The Fund may engage in other investment practices that may involve additional risks and you should review the Fund prospectus for a complete description.


Insights & Analysis

Commentary

A Word On The Markets as of Jun 30, 2016

Performance of the global equity markets in the second quarter of 2016 can be summarized in one word - Brexit. The U.K. referendum that resulted in Britain's decision to leave the European Union sent the markets into a June swoon after two very non-volatile months in April and May.

Brexit polls created the initial volatility and optimism late in the quarter, but the final vote cemented an unexpected outcome. Extreme currency fluctuations across the globe added to the volatility, with notable moves in the sterling, euro, yen and U.S. dollar.

Despite the roil, global markets were still able to post modest gains in the quarter. The MSCI World Index10 ended the period up 1.2% (total return), an improvement compared to the first quarter, in which that index was negative.

Brexit catalyzed an investor stampede to a "risk-off" strategy, buying defensive names and selling uncertainty. As a result, health care stocks performed well during the period. The MSCI World Health Care Index1 returned 5.6% in the quarter, compared to broader indices, which trailed. Commensurately, large-cap pharmaceutical stocks were up 7.9% in the period (as measured by the NYSE Arca Pharmaceutical Index11). However, biotechnology stocks sold off in response to Brexit. The NASDAQ Biotech Index12 was particularly volatile, with a greater than -15% move (peak to trough) within the quarter, reaching a multiyear low and closing down 1.1%.

Performance Summary 

For the second quarter of 2016, the Fund's return was 3.7% for Class A shares at net asset value, as compared to the MSCI World Health Care Index return of 5.6%.

  • Positive returns in the quarter came from a variety of sources, but most notable was the medical device space, in which both positioning and stock picking generated absolute and relative positive performance.
  • Underperformance relative to the Index was due to sector positioning in large-cap pharmaceuticals (underweight) and stock picking in large-cap biotechnology stocks, partially offset by stock picking in specialty cap biotech stocks.
  • Negative alpha generation was primarily due to positioning in large-cap pharmaceutical stocks. Our underweight positioning did not capture the large rebound that occurred in the period, although large-cap pharma was a positive absolute contributor.
  • Stock picking in large-cap biotechnology also contributed to underperformance, due to unexpected negative catalysts.

Historical Returns (%)as of Jun 30, 2016

Annualized
1 Mo. 3 Mos. YTD 1 Yr. 3 Yrs. 5 Yrs. 10 Yrs.
Fund at NAV -2.37 3.73 -7.95 -10.92 16.47 14.44 11.08
Fund w/Max Sales Charge -7.95 -2.20 -13.26 -16.06 14.21 13.08 10.42
MSCI World Health Care Index1 0.80 5.59 -1.61 -4.60 12.87 13.94 8.84
Past performance is no guarantee of future results. Investment return and principal value will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. Performance is for the stated time period only; due to market volatility, the Fund's current performance may be lower or higher than quoted. Returns are historical and are calculated by determining the percentage change in net asset value (NAV) with all distributions reinvested. Returns for other classes of shares offered by the Fund are different. Performance less than or equal to one year is cumulative. Max Sales Charge: 5.75%.

Fund Factsas of Jun 30, 2016

Class A Inception 07/26/1985
Expense Ratio2 1.34%

Contributors 

The largest contributors to performance were mostly large-cap stocks from the medical device and pharmaceutical sectors.

  • The combination of positive first-quarter earnings results and increased investor confidence in future growth drove the outperformance of Boston Scientific shares.
  • Investor enthusiasm continued to build for the sales potential of Opdivo, Bristol-Myers Squibb's blockbuster cancer drug. The stock reached a 52-week high in the quarter.
  • Robotic procedure volumes, an improving gross margin profile and diminished investor concern over competitive robotic system launches all led to strong share price performance for surgical robot maker Intuitive Surgical, Inc.
  • Shares in Abbvie Inc. traded higher in the quarter, as investors recognized the stock as a value play with important catalysts looming in the second half of 2016.
  • Shares in medical spine company NuVasive, Inc. outperformed due to solid earnings results, favorable acquisitions and improving market dynamics.

Detractors 

Detractors in the quarter stemmed from a mix of idiosyncratic negative catalysts, while underweight positioning in some notable large-caps created some alpha headwinds.

  • Shares in Allergan PLC gapped lower in the quarter after its planned merger with Pfizer fell through due to prohibitive federal regulatory changes.
  • Alexion Pharmaceuticals, Inc. fell more than 15% after the company's investigational compound for the treatment of myasthenia gravis failed in late stage clinical trials.
  • Shares of Illumina Inc. gapped almost 25% lower after the company preannounced lower-than-expected first-quarter revenue estimates due to lower sales of genome sequencers.
  • Shares of biotech giant, Biogen Inc. fell after the company reported a failed trial in multiple sclerosis with the novel agent opicinumab, commonly referred to as "anti-LINGO."
  • Negative alpha came from stocks with notable strength and size in the Index, but which were underweighted in the Fund, including JNJ, Pfizer, Medtronic, Novartis and Merck.

Investment Outlook And Fund Positioning 

In the near term, we expect the volatility from Brexit to partially abate, and investors to refocus on fundamentals. Interest rates and the hunt for yield will also be debated, as will global currency moves. Geopolitical uncertainty will also influence market returns.

Longer term, the key debate will likely be, what is best strategy for market returns? Will "risk-off" remain, but with only marginal returns? Or, will investors get more aggressive and revert to "risk-on" to seek higher returns?

Health care is one sector that may offer alternatives for both. Large-cap stocks possess modest but stable growth and attractive dividend yields. SMID-cap stocks, particularly biotechnology stocks, can rerate significantly higher vis-a-vis clinical catalysts and M&A.

Top 10 Holdings (%)3,4as of Jun 30, 2016

Boston Scientific Corp 6.27
AbbVie Inc 5.24
Intuitive Surgical Inc 5.03
Ono Pharmaceutical Co Ltd 4.79
Allergan plc 4.36
Amgen Inc 4.24
HCA Holdings Inc 3.78
Bristol-Myers Squibb Co 3.58
Eli Lilly & Co 3.33
Alexion Pharmaceuticals Inc 3.20
Total 43.82

The views expressed in this report are those of portfolio manager(s) and are current only through the date stated at the top of this page. These views are subject to change at any time based upon market or other conditions, and Eaton Vance disclaims any responsibility to update such views. These views may not be relied upon as investment advice and, because investment decisions are based on many factors, may not be relied upon as an indication of trading intent on behalf of any Eaton Vance fund. This commentary may contain statements that are not historical facts, referred to as "forward looking statements". The Fund's actual future results may differ significantly from those stated in any forward-looking statement, depending on factors such as changes in securities or financial markets or general economic conditions, the volume of sales and purchases of Fund shares, the continuation of investment advisory, administrative and service contracts, and other risks discussed from time to time in the Fund's filings with the Securities and Exchange Commission.

Portfolio profile subject to change due to active management. Percentages may not total 100% due to rounding. Fund invests in an affiliated investment company (Portfolio) with the same objective(s) and policies as the Fund. References to investments are to the Portfolio's holdings.

About Risk 

Fund performance is sensitive to stock market volatility. Because the Fund investments may be concentrated in a particular industry, the Fund share value may fluctuate more than that of a less concentrated fund. Investments in foreign instruments or currencies can involve greater risk and volatility than U.S. investments because of adverse market, economic, political, regulatory, geopolitical or other conditions. Smaller companies are generally subject to greater price fluctuations, limited liquidity, higher transaction costs and higher investment risk than larger, established companies. No Fund is a complete investment program and you may lose money investing in a Fund. The Fund may engage in other investment practices that may involve additional risks and you should review the Fund prospectus for a complete description.

Attribution

No attribution information is currently available.

Portfolio profile subject to change due to active management. Percentages may not total 100% due to rounding. Fund invests in an affiliated investment company (Portfolio) with the same objective(s) and policies as the Fund. References to investments are to the Portfolio's holdings.

About Risk 

Fund performance is sensitive to stock market volatility. Because the Fund investments may be concentrated in a particular industry, the Fund share value may fluctuate more than that of a less concentrated fund. Investments in foreign instruments or currencies can involve greater risk and volatility than U.S. investments because of adverse market, economic, political, regulatory, geopolitical or other conditions. Smaller companies are generally subject to greater price fluctuations, limited liquidity, higher transaction costs and higher investment risk than larger, established companies. No Fund is a complete investment program and you may lose money investing in a Fund. The Fund may engage in other investment practices that may involve additional risks and you should review the Fund prospectus for a complete description.


Management

Biography

Jason Kritzer, CFA

Vice President, Eaton Vance Management
Joined Eaton Vance 2012

Jason Kritzer is a vice president of Eaton Vance Management and an equity analyst on Eaton Vance's growth team. He is responsible for coverage of the pharmaceutical, health care equipment and biotechnology industries. He joined Eaton Vance in 2012.

Jason began his career in the investment management industry in 1999. He was previously affiliated with BlackRock, Inc. as a director and equity analyst and Putnam Investments as an equity research analyst.

Jason earned a B.S.B.A. from Boston University, School of Management and an MBA from Columbia University, School of Business. He is a member of the Columbia Business School Ambassador Program. He is a CFA charterholder.

Education
  • B.S.B.A. Boston University
  • M.B.A. Columbia University
Experience
  • Managed Fund since 2016
 
Biography
Samantha Pandolfi, CFA

Samantha Pandolfi, CFA

Vice President, Eaton Vance Management (International) Limited
Joined Eaton Vance 2015

Samantha Pandolfi is a vice president of Eaton Vance Management (International) Limited and portfolio manager and research analyst on Eaton Vance's global equity team. She is primarily responsible for covering the health care sector for global large-cap portfolios. She joined Eaton Vance in 2015.

Samantha began her career in the investment management industry in 2000. Before joining Eaton Vance, she was an executive director and European and global health care portfolio manager at Goldman Sachs Asset Management (GSAM) for 15 years. She has also covered apparel/luxury goods, support services, leisure and cosmetics.

Samantha earned her J.D. from Universita' degli Studi La Sapienze and holds an MBA from INSEAD. She is a CFA charterholder.

Education
  • M.B.A. INSEAD
  • J.D. Universita' degli Studi La Sapienze
Experience
  • Managed Fund since 2016

Literature

Literature

Fact Sheet

Commentary

Annual Report

Full Prospectus

Holdings-1st or 3rd fiscal quarters-www.sec.gov

SAI

Semi-Annual Report

Summary Prospectus

XBRL


 

loading

We apologize for the inconvenience but we are experiencing a technical issue.

We are working on a solution. Please try again later.

If you require further assistance, please call:
1-800-836-2414.

You have already upgraded your account. Please login using the link at the top of the page.

    Your download will begin when this window is closed.

    You have successfully un-subscribed from .

    As a subscriber, you are one step away from getting more access and control. Register now by simply creating a password below.

    Passwords must be 8 to 20 alphanumeric characters, including a special character:
    ! @ # $ % ^ & * ( ) - _ = + , < . > ?.

    Cancel

    Trouble registering? Call 1-800-836-2414.

    Congratulations! You are registered.

    We have sent a verification email to . Please check your e-mail and click on the secured link to verify your account and complete the registration process.

    Trouble receiving the verification email? Call 1-800-836-2414.

    Congratulations!

    We are pleased to grant you access to this Eaton Vance website.

    Please click here to be logged in with your username .

    A verification email has been sent.

    You have requested a change to your password. In order to process this request, a verification email has been sent to . When you receive this email, please click the link contained within the email to start the password reset process.

    Trouble signing in? Call 1-800-836-2414.

    This account is restricted.

    Your account has limited access. You currently have access to content for:

    Firm restriction.

    This document has not been approved at your firm. We can not complete your subscription request at this time. Please try again later.


    If you need further assistance, please call 1-800-836-2414.

    This account has been updated.

    Your account has been updated to use your new email address .

    We have sent a verification email to with a verification link to confirm the change.

    Trouble receiving the verification email? Call 1-800-836-2414.

    This email account has not been verified.

    Your account has not yet been activated. We have sent a verification email to . If you'd like us to resend this, please click the Resend Email button below.

    Trouble receiving the verification email? Call 1-800-836-2414.

    Cancel

    Thank you.

    An e-mail verification has been re-sent to . Please check your e-mail and follow the instructions to complete the registration process.

    Trouble receiving the verification email? Call 1-800-836-2414.

    An email has been sent to the email address containing a link to verify your credentials. Please check your e-mail and click on the secured link to complete your request.

    Trouble receiving the verification email? Call 1-800-836-2414.

    Re-verification Required

    For security purposes we could not complete your request. Please click here to receive a new link to access the requested content.

    A new email has been sent to the email address containing a link to re-verify your credentials. Please check your e-mail and click on the secured link to complete your request.

    Trouble receiving the verification email? Call 1-800-836-2414.

    Verification Accepted

    You have been granted access to the requested content.

    Remember Me

    Click here to remain recognized on this device for future visits to EatonVance.com

    Do Not Remember Me

    Click here if you are using a Public Computer or Shared Device.

    Trouble receiving the verification email? Call 1-800-836-2414.

    Cancel

    Subscribe to new content: Register

    Please check the Fund Literature that you would like to subscribe to. Your subscriptions can be managed on your profile page.

    Subscribe All

    Thank you for downloading

    If your download did not start automatically, please click here.

    Stay on top of your game.

    Receive email notifications when the  is updated by clicking the subscribe button.

    Close

    Thank you for subscribing

    We have sent a verification email to . Please check your e-mail and click on the secured link to verify your subscription.

    Un-subscription request

    We have sent a verification email to . Please check your e-mail and click on the secured link to verify your request.

    Stay on top of your game.

    You have selected to receive email notifications for:

    Cancel

    Subscribe to new content: Register

    Stay on top of your game.

    You are currently "Opted Out" of all Eaton Vance email communications. If you would like to be alerted of updates to your new subscription, please Opt In:

    Close

    Enter your e-mail address to reset your password.

    Already have an account?
    Subscribe to new content: Register

    Trouble registering? Call 1-800-836-2414.

    Simply enter your e-mail address to register.

    Cancel

    Already have an account?

    Register for more access and control.
    • Elevate your business practice with materials from the Advisor Institute.
    • Learn more with exclusive videos, conference calls, and the latest insights.
    • Follow products, get product notifications, and manage your Eaton Vance communications.
    Please wait while the data is being prepared for download.
    loading
    This message will automatically close when your file is ready.
    Please enter a new email.

    Trouble signing in? Call 1-800-836-2414.

    Investment Professionals

    Register Now

    Already have an account? .

     

    Symbol:  

    NAV as of